Adipomimetin as viable alternative for Metformin and Sulphonylureas R1

Adipomimetin, a plant-derived protein, presents a viable alternative to Metformin and Sulphonylureas as a first-line treatment for Type-II diabetes. Unlike conventional anti-diabetic medications, which modify metabolic processes and are prone to side effects, Adipomimetin supplements the action of the human hormone Adiponectin by activating AMP Kinase. This natural activation process helps regulate blood glucose levels, lipid metabolism, body weight, and overall health, without the adverse effects associated with Metformin and Sulphonylureas, such as lactic acidosis, beta-cell destruction, and cardiovascular risks. Adipomimetin’s safety and efficacy as a non-chemical supplement make it suitable for managing hyperglycemia in pre-diabetic and early-stage Type-II diabetes patients. It can also be administered alongside other anti-diabetic drugs in advanced stages of the disease, potentially reducing the required dosages. Additionally, Adipomimetin addresses multiple metabolic conditions, including hyperlipidemia, atherosclerosis, hypertension, heart disease, and obesity, positioning it as a comprehensive treatment option for lifestyle-related diseases.